Skip to Content

Posts tagged with "Clinical Trials"

  • Clinical Trials

    The FDA’s Latest Actions and Problems

    It’s been clear for many years now that some drug companies are abusing the “restricted distribution” idea to keep generic competitors from being able to enter their markets. That, in fact, was a basic part of Martin Shkreli’s entire business plan, but guess what? He was not the first person to think of doing that… Read More
  • Cancer

    A Glioblastoma Vaccine? Not Yet.

    If you get your biomedical breaking news from the British press, you will have heard all about a very promising vaccine treatment for glioblastoma. (“Remarkably promising” – BBC. “Could add years” – The Guardian. And there’s the Daily Mail (naturally), The Independent, and more). That would be good news, b… Read More
  • Clinical Trials

    Federal Right to Try

    So it looks like a Right-to-Try bill is going to be signed into law. People who have been advocating this for years will now get a chance to see how it works out in practice – and in fact, I would encourage them to go ahead and put down some predictions about what they think… Read More
  • Alzheimer's Disease

    Merck’s BACE-Inhibitor Alzheimer’s Wipeout

    I mentioned last year that Merck’s BACE inhibitor trial for Alzheimer’s had been stopped for futility. Now here’s the full writeup in NEJM, and futility appears to have been le mot juste. There were two treatment groups (12 mg and 40 mg), and in neither one did the ADAS-cog or ADAS-ADL scores (scales for degree… Read More
  • Cancer

    Cancer Sequencing Hype And Reality

    This piece in Science says something that needs to be said louder and more publicly. If you live in the US, you’ve surely seen various cancer treatment centers talking about their personalized therapy plans, and especially how they’ll tailor things to your DNA sequence and so on. You would get the impression that we have… Read More
  • Cancer

    IDO Appears to Have Wiped Out

    We have the answer to a question posed here earlier this month. That was after the Merck/Incyte failure of a combination of Keytruda and Incyte’s IDO (indole 2,3-dioxygenase) inhibitor. That mechanism was supposed to increase T-cell activity, but the trial showed it to have no effect on Keytruda’s efficacy at all. Earlier IDO trials had… Read More
  • Clinical Trials

    Tighten Up Your Numbers!

    There’s clearly something wrong with the way that statistics get handled and interpreted in scientific studies, and there have been many warnings. But change in this area is a hard thing to bring about. Biocentury has a good interview with someone who can tell you about that, John Ioannidis, of scientific reproducibility fame. He’s rec… Read More
  • Alzheimer's Disease

    Bad Investments

    Here are some sequels to stories I’ve written about here, things that have had some new chapters added to them. First off, this 2015 post mentions the steep drop in shares of Clovis Biotechnology, brought on by a rather sudden revision in the announced clinical performance of their lead drug (the covalent kinase inhibitor rociletinib). Well… Read More
  • Cancer

    IDO Inhibitors Hit a Wall

    Friday brought some very unwelcome news in oncology. I’ve written about IDO inhibitors before, partly in the context of an odd situation between Incyte and Flexus, and partly in response to a recent failed trial of a compound from NewLink. That last one shook people up a bit, but (as I mentioned in the post) Read More
  • Business and Markets

    One Of Those Binary Events for AbbVie

    Back in late 2015, I wrote about cancer stem cells, the idea that some tumors are driven by populations of slow-dividing stem cells. The theory has been that these are always going to be in there fighting against your efforts to kill off the downstream tumor cells, so unless you find a way to target… Read More
...234...